Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.

Expert opinion on pharmacotherapy - 1 Apr 2015

Jiang Minghuan, You Joyce H S

Abstract excerpt

INTRODUCTION: Clopidogrel is an antiplatelet agent widely prescribed for acute coronary syndrome (ACS), and it is activated by the CYP enzyme system to active metabolite. CYP2C19 loss-of-function (LOF) allele(s) affect the responsiveness of clopidogrel, but not the new antiplatelet agents (prasugrel and ticagrelor). We reviewed the pharmacoeconomic studies on genotype-guided use of new antiplatelet agents. AREAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome
Share to Adenosine
Share to Clopidogrel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Percutaneous Coronary Intervention

Share to Prasugrel Hydrochloride

Share to Thiophenes

Share to Ticagrelor

Share to Ticlopidine

Source

Identifiers

PMID: 25660101
DOI: 10.1517/14656566.2015.1013028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.PMID 25660101Read ↗

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.Semantic proximity Read ↗

CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.Semantic proximity Read ↗

Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.Semantic proximity Read ↗

Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.Semantic proximity Read ↗

CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.Semantic proximity Read ↗

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.Semantic proximity Read ↗

CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.Semantic proximity Read ↗

Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.Semantic proximity Read ↗

The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.Semantic proximity Read ↗

Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.Semantic proximity Read ↗

A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.